阿帕替尼联合卡培他滨二线治疗晚期胆管癌的效果、安全性及对疾病相关指标表达的影响  

The Effect and Safety of Apatinib Combined with Capecitabine in Second-line Therapy of Advanced Cholangiocarcinoma and Influence on Expression of Disease Related Indexes

作　　者：邓建华 赵新华[1] DENG Jianhua;ZHAO Xinhua(Jiujiang NO.1 People's Hospital,Jiangxi Province,Jiujiang 332000,China)

机构地区：[1]江西省九江市第一人民医院,江西九江332000

出　　处：《中国医学创新》2023年第18期1-4,共4页Medical Innovation of China

基　　金：九江市重点研发计划-指导性计划项目(S2021ZDYFN175)。

摘　　要：目的:探究阿帕替尼联合卡培他滨二线治疗晚期胆管癌的效果、安全性及对疾病相关指标表达的影响。方法:将2020年6月-2022年6月九江市第一人民医院的80例晚期胆管癌患者根据随机数字表法分为对照组和观察组,每组40例。对照组采用替吉奥进行治疗,观察组则采用阿帕替尼联合卡培他滨进行治疗。比较两组的疾病控制率、毒副反应发生率、治疗前后的疾病相关指标肿瘤标志物[糖类抗原19-9(CA19-9)、癌胚抗原(CEA)及糖类抗原50(CA50)]及凋亡相关因子[肝癌衍生生长因子(HDGF)及环氧合酶-2(COX-2)]。结果:观察组的疾病控制率显著高于对照组,毒副反应(呕吐、腹泻及皮疹)发生率均显著低于对照组,差异均有统计学意义(P<0.05);治疗前两组的疾病相关指标比较,差异均无统计学意义(P>0.05),治疗1个周期及2个周期后观察组的上述疾病相关指标均持续降低,且观察组均显著低于对照组,差异均有统计学意义(P<0.05)。结论:阿帕替尼联合卡培他滨二线治疗晚期胆管癌的效果较好,安全性较高,且可显著改善疾病相关指标的表达,在晚期胆管癌二线治疗中的应用价值较高。Objective:To investigate the effect and safety of Apatinib combined with Capecitabine in second-line therapy of advanced cholangiocarcinoma and influence on expression of disease related indexes.Method:A total of 80 patients with advanced cholangiocarcinoma in Jiujiang NO.1 People's Hospital from June 2020 to June 2022 were divided into control group and observation group by the random number table,with 40 cases in each group.The control group was treated with Tegafur,the observation group was treated with Apatinib combined with Capecitabine.Then the disease control rates,toxic and side effects rates and disease related indexes[tumor markers carbohydrate antigen 19-9(CA19-9)],carcinoembryonic antigen(CEA)and carbohydrate antigen 50(CA50)and apoptosis-related factors[hepatoma-derived growth factor(HDGF)and cyclooxygenase-2(COX-2)]before and after the treatment of two groups were compared.Result:The disease control rate of observation group was significantly higher than that of control group,the toxic and side effects(vomiting,diarrhea and rash)rates were significantly lower than those of control group,the differences were statistically significant(P<0.05);the disease related indexes of two groups before the treatment were compared,the differences were not statistically significant(P>0.05),the disease related indexes of observation group at first and second cycle after the treatment were continuously improved,and those of observation group were significantly lower than those of control group,the differences were statistically significant(P<0.05).Conclusion:The effect of Apatinib combined with Capecitabine in second-line therapy of advanced cholangiocarcinoma is better,and its safety is higher,it can significantly improve the expression of disease related indexes,so its application value in second-line therapy of advanced cholangiocarcinoma is higher.

关 键 词：阿帕替尼 卡培他滨 二线治疗 晚期胆管癌 安全性 

分 类 号：R735.8[医药卫生—肿瘤]